Study of Tissue and Blood Samples From Patients With Low-Grade Glioma

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is looking at tissue and blood samples from patients with low-grade glioma.

Detailed Description
-----------------
OBJECTIVES: Evaluate the diagnostic and prognostic relevance of alterations of specific chromosomes and chromosomal regions including 7, 9p, 10p, 10q, 13q, 17p, 17q, 19q, 22q, X, and Y, using PCR analysis of microsatellite repeats and FISH. Evaluate the diagnostic and prognostic relevance of DNA ploidy by flow cytometric analysis; compare with ploidy determination by FISH. Assess the diagnostic and prognostic relevance of various markers of cellular proliferation and cellular function including flow cytometric determination of %S-phase, %G2M, and immunohistochemical evaluation of PCNA, Ki-67, and p53.

Official Title
-----------------
Diagnostic and Prognostic Markers in Low-Grade Gliomas

Conditions
-----------------
Brain and Central Nervous System Tumors

Intervention / Treatment
-----------------
* Genetic: fluorescence in situ hybridization
* Genetic: loss of heterozygosity analysis
* Genetic: polymerase chain reaction
* Other: flow cytometry
* Other: immunohistochemistry staining method


Participation Criteria
=================
Eligibility Criteria
-----------------
Paraffin-embedded tumor tissue blocks of patients enrolled in NCCTG 86-72-51 or 93-72-02 and who had the diagnosis of low-grade glioma. Patients who have the diagnosis of low-grade glioma with an available paraffin- embedded tumor tissue block enrolled in prospective NCCTG and Mayo studies.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Single group<br>Previously preserved paraffin-embedded tissue blocks are obtained and used for biomarker studies. Blood samples obtained during treatment are also obtained. Loss of heterozygosity of specific chromosomal regions are performed using PCR analysis of microsatellite repeats (41,118-120) on DNA extracted from the paraffin-embedded archival specimens. FISH and flow cytometry may also be used to assess chromosomal loss of deletion. Immunohistochemistry is also performed. | Genetic: fluorescence in situ hybridization<br> <br> Genetic: loss of heterozygosity analysis<br> <br> Genetic: polymerase chain reaction<br> <br> Other: flow cytometry<br> <br> Other: immunohistochemistry staining method<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Alterations in chromosomes 7, 9p, 10, 17, 19q, X, or Y as determined by FISH |  | baseline | 
| Loss of chromosomal materials in chromosomes 9p, 10, 13, 17, or 22 by PCR analysis |  | baseline | 
| Levels of PCNA, Ki-67 (MIB-1), or mutated p53 by immunostaining with monoclonal antibodies |  | baseline | 
| DNA ploidy by FISH and flow cytometry |  | baseline | 
| Percentage of cells in S-phase or G2M-phase as measured by flow cytometry |  | baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
childhood low-grade cerebellar astrocytoma, childhood low-grade cerebral astrocytoma, childhood mixed glioma, adult mixed glioma, adult diffuse astrocytoma, childhood oligodendroglioma, adult oligodendroglioma